Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

HealthDay News — Cannabis use is associated with major adverse cardiovascular events (MACE), according to a systematic review based on real-world data published online June 17 in Heart.

Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics ...

Through August 16, 2024, the Agency has identified 13 cases worldwide of hyperthermia associated with scopolamine patches.

The Food and Drug Administration (FDA) has approved Harliku ™ (nitisinone) for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria.

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.